Pharmaceutical News

RSS

Statins may play role in lowering risk of clot-related diseases: Study

Individuals at risk for clot-related diseases may benefit from taking common cholesterol-lowering drugs known as statins, according to a study conducted by researchers at the University of Connecticut.

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

Amended class action complaint against Pfizer

Robbins Geller Rudman & Dowd LLP ("Robbins Geller") today announced that an amended class action complaint will be filed in the United States District Court for the Southern District of New York. The amended complaint will be on behalf of purchasers of Pfizer Inc. publicly traded securities during the period between January 19, 2006 and January 23, 2009.

15 May 2010

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Protox Therapeutics Inc. a leader in the development of receptor targeted fusion proteins, today released financial results for the first quarter 2010, ended March 31, 2010. "The first quarter of 2010 marked significant achievements for the company, namely the announcement of positive top-line results from the TRIUMPH study and the subsequent completion of a five million dollar financing," said Dr. Fahar Merchant, President and CEO of Protox.

15 May 2010

Biovest International announces filing of proposed Plan of Reorganization

Biovest International, Inc. today announced that the Company filed its proposed Plan of Reorganization with the U.S. Bankruptcy Court for the Middle District of Florida, Tampa Division. With this filing, Biovest is positioned to emerge from Chapter 11 protection this summer as a fully restructured company.

15 May 2010

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.

15 May 2010

Dyadic International reports $1.1 million net loss for first-quarter 2010

Dyadic International, Inc., a leading-edge biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the quarter ended March 31, 2010.

15 May 2010

Small anti-abortion advocacy group flexes muscle in midterm elections

The Washington Post reports on the increasingly important role of a small antiabortion advocacy group, the Susan B. Anthony List, which is targeting Senate Majority Leader Harry Reid in his bid for re-election.

15 May 2010

Lotus Pharmaceuticals first-quarter net income up 38%

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China today reported its financial results for the first quarter ended March 31, 2010.

15 May 2010

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen Inc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa® (zoledronic acid).

15 May 2010

U.S. healthcare practitioners can resume use of Rotarix, says FDA

GlaxoSmithKline announced that the Food and Drug Administration has determined that U.S. healthcare practitioners can resume the use of Rotarix (Rotavirus Vaccine, Live, Oral), effective immediately. This action supersedes the FDA's recommendation from March 22, 2010 and reflects the agency's assessment that the presence of porcine circovirus type 1 in the vaccine poses no safety risk.

15 May 2010

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.

15 May 2010

FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Cinacalcet HCl Tablets 30, 60 & 90 mg.

15 May 2010

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

Direct Relief International announced today that CSL Behring has donated life-saving medicines valued at more than $100,000 to assist earthquake victims in Haiti who are at risk of tetanus or hepatitis B infections. The products will be used in clinics at Hopital Albert Schweitzer in Deschapelles.

14 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.

14 May 2010

FDA grants tentative approval for Impax Laboratories' generic Opana ER

Impax Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of Opana® ER (oxymorphone hydrochloride) 5, 7.5, 10, 15, 20, 30 and 40 mg tablets.

14 May 2010

Revolutionary technology to protect skin stem cells and combat chronological aging

Emerge Labs presents a revolutionary technology that protects skin stem cells and combats chronological aging. The breakthrough patent-pending active ingredient, PhytoCellTec Solar Vitis, boosts the production of human skin stem cells, protects human skin stem cells against UV radiation, and fights photo-aging, thus decreasing wrinkles and producing younger, fresher looking skin.

14 May 2010

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

The effects of multivitamins are most often researched in the elderly. This is one of very few studies to assess the relationship between supplementation with vitamins/minerals and psychological functioning in healthy groups of non-elderly adults. This study shows how a proprietary multivitamin and mineral supplement improves mood and mental performance while also reducing stress, mental tiredness and fatigue in healthy males.

14 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Pharmaceutical News

Statins may play role in lowering risk of clot-related diseases: Study

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Amended class action complaint against Pfizer

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Biovest International announces filing of proposed Plan of Reorganization

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Dyadic International reports $1.1 million net loss for first-quarter 2010

Small anti-abortion advocacy group flexes muscle in midterm elections

Lotus Pharmaceuticals first-quarter net income up 38%

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

U.S. healthcare practitioners can resume use of Rotarix, says FDA

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

FDA grants tentative approval for Impax Laboratories' generic Opana ER

Revolutionary technology to protect skin stem cells and combat chronological aging

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News